Evidence map›Paper›PMID 41403244›Full record

ArticleInternational journal of surgery (London, England)2025

Integrated multi-omics analysis revealed that SMARCAL1 serves as an immune related prognostic marker and promotes liver cancer growth via the Hippo/YAP signaling axis.

Tingting Huang, Meng Tang, Qiulin Tang, Ye Di, Jiayu Wang, Yichun Duan, Chenliang Zhang, Feng Bi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of surgery (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Tingting HuangDivision of Abdominal Cancer, Department of Medical Oncology, Cancer Center and Laboratory of Molecular Targeted Therapy in Oncology, West China Hospital, Sichuan University, Chengdu, China.
Meng TangDepartment of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Qiulin TangDivision of Abdominal Cancer, Department of Medical Oncology, Cancer Center and Laboratory of Molecular Targeted Therapy in Oncology, West China Hospital, Sichuan University, Chengdu, China.
Ye DiDivision of Abdominal Cancer, Department of Medical Oncology, Cancer Center and Laboratory of Molecular Targeted Therapy in Oncology, West China Hospital, Sichuan University, Chengdu, China.
Jiayu WangSchool of Medicine and Health, Harbin Institute of Technology, Harbin, China.
Yichun DuanDivision of Abdominal Cancer, Department of Medical Oncology, Cancer Center and Laboratory of Molecular Targeted Therapy in Oncology, West China Hospital, Sichuan University, Chengdu, China.
Chenliang ZhangDivision of Abdominal Cancer, Department of Medical Oncology, Cancer Center and Laboratory of Molecular Targeted Therapy in Oncology, West China Hospital, Sichuan University, Chengdu, China.
Feng BiDivision of Abdominal Cancer, Department of Medical Oncology, Cancer Center and Laboratory of Molecular Targeted Therapy in Oncology, West China Hospital, Sichuan University, Chengdu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo illustrate the potential role of SMARCAL1 on malignancy, immune regulation and related pathway in liver cancer.

methodsIn our study, we examined the expression patterns, clinical features and survival analysis from TCGA and GEO datasets. Immunedeconv package was employed for evaluating the association between the immune infiltration components and SMARCAL1 expression. Knockdown experiment was performed to examine the impacts of SMARCAL1 on cell viability, apoptosis, and classical Hippo-YAP pathway. Meanwhile, the association between SMARCAL1 expression and drug sensitivity was constructed through CTRP, PRISM and GDSC databases. Finally, we also discovered novel inhibitors of SMARCAL1 activity against liver cancer and YAP activity through virtual screening and western blot assay.

resultsSMARCAL1 exhibited increased expression in LIHC and was linked to unfavorable outcomes for patients. SMARCAL1 expression was associated with specific clinical features, drug sensitivity, and immune microenvironment characteristics. Additionally, SMARCAL1 was closely related to the activity of Hippo-YAP pathway. Finally, deferoxamine mesylate and its parent compound deferoxamine were identified as candidate inhibitors of SMARCAL1 activity, showing significant ability to inhibit proliferation and the downstream protein YAP1.

conclusionTargeting SMARCAL1 could be a promising strategy for liver cancer treatment.

Indexed as

hippo-YAP pathwayimmune infiltrationliver cancerproliferationSMARCAL1

Identifiers

PMID41403244
PMCPMC13105517

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.